Searchable abstracts of presentations at key conferences in endocrinology

ea0063gp45 | Metabolic Syndrome and Hypoglycaemia | ECE2019

Hypoglycemia and dementia risk in older patients with type 2 diabetes: a propensity-score matched analysis of a population-based cohort study

Jin Han Seung , Kim Young-Gun , Young Moon So

Background: Type 2 diabetes mellitus (T2DM) is associated with an increased risk for dementia. The effects of hypoglycemia on dementia are controversial. Thus, we evaluated whether hypoglycemia increases the risk for dementia in senior patients with T2DM.Methods: We used the Korean National Health Insurance Service Senior cohort, which includes >10% of the entire senior population of South Korea. In total, 7,752 patients who had ever experienced hypo...

ea0056gp54 | Bone and Osteoporosis | ECE2018

Effect of inhaled corticosteroidson trabecular bone score in patients with asthma

Choi Yong Jun , Lee Hyun Young , Ye Young-Min

Background: In asthmatic patients, in addition to conventional risk factors for osteoporosis, inflammatory factors and treatment with corticosteroids may also lead them to further bone loss. The trabecular bone score (TBS) is a new indirect parameter of bone quality. There has been no study which evaluates TBS in asthmatic patients according to use of corticosteroids.Objective: This study evaluated the TBS according to the severity of asthma and the corr...

ea0063p337 | Thyroid 1 | ECE2019

The serum thyroglobulin level after discontinuation of two weeks of thyroid hormone in patients with differentiated thyroid cancer can be used to determine the therapeutic dose of radioiodine

Song Heesung , Lee Ji Young

Purpose: This retrospective study is intended to determine the dose of radioactive iodine using thyroglobulin levels measured after two weeks of thyroid hormone withdrawal in patients with differentiated thyroid cancer. Methods : Patients who were diagnosed as differentiated thyroid cancer and treated with radioiodine after total thyroidectomy were enrolled. Serum thyroglobulin test (preTG; ng/dl) was performed 1 week before radioiodine treatment and 2 w...

ea0070aep996 | Thyroid | ECE2020

Comparison of therapeutic radioiodine dose to ablation response in differentiated thyroid cancer patients with cut-off serum thyroglobulin level after two weeks of levothyroxine withdrawal

SONG Heesung , Young Lee Ji

Purpose: This retrospective study is evaluated the efficacy of three doses of I-131 (1110 MBq vs 3700 MBq vs 5550 MBq) in differentiated thyroid carcinoma patients with cut-off serum thyroglobulin (TG) level after two weeks of thyroid hormone withdrawal for postoperative thyroid remnant ablation.Methods: A total of 97 patients with differentiated thyroid cancer treated with total thyroidectomy and radioactive iodine (RAI) therapy...

ea0009p92 | Endocrine tumours and neoplasia | BES2005

Is survivin regulated by c-Myc?

Cosgrave N , Hill A , Young L

Introduction: In endocrine tumours, such as that of the breast, the protein survivin has emerged as a unique regulator of cell death. We have previously shown that bFGF regulates survivin expression through the MAP kinase cascade. The transcriptional complex myc/max is an oncogene that lies downstream of the MAP kinase pathway suggesting a possible role in survivin's regulation.Aim: To determine if bFGF can mediate survivin expression by signalling throu...

ea0091wa6 | Workshop A: Disorders of the hypothalamus and pituitary | SFEEU2023

Trying to conceive: is the prolactinoma to blame?

Young Ekenechukwu , Bell Richard , Kong Ngai

A 47 year old lady referred to the endocrine clinic following raised prolactin levels picked up on investigation for infertility in 2013. She had irregular periods with cycle length up to 50 days. Peak prolactin following diagnosis was 1309mIU/l. She had no headaches, visual problems or galactorrhoea. An MRI head had picked up a 6.3 x 6.9 x 8.3mm right sided pituitary mass in 2013. She was commenced on Bromocriptine. Her periods normalised on treatment to 24 to 25 day cycles. ...

ea0063p260 | Pituitary and Neuroendocrinology 1 | ECE2019

Hyperglycemia in patients with acromegaly treated with pasireotide LAR

Yu Seung Hee , Lee Ki Young

Pasireotide long-acting release (LAR) is a multireceptor-targeted somatostatin receptor ligand approved for treatment of patients with acromegaly. In some clinical reports, pasireotide LAR has been shown to regulate biochemical outcomes more than other somatostatin receptor ligands. However, hyperglycemia was frequently observed in pasireotide LAR treated patients with acromegaly. Three patients were treated with pasireotide LAR to regulated biochemical parameters of acromegal...

ea0041ep869 | Pituitary - Basic | ECE2016

Relationship between Insulin and somatostatin secretory response to Glucagon-like peptide-1 (GLP-1) and glucose concentration in perifused rat pancreatic islet cells

Park So Young , Kim Sung-Woon

Objective: The exogenous somatostatin inhibits insulin secretion in pancreatic cell and could lead to hyperglycemia. But, Glucagon-like peptide-1 (GLP-1) has insulinotropic actions despite stimulating somatostatin secretion in δ cell. So, we examined whether there is a time difference of insulin and somatostatin secretion after GLP-1 stimulation or secretion rate difference of insulin and somatostatin depending on GLP-1 concentration and glucose concentration ins...

ea0038p153 | Neoplasia, cancer and late effects | SFEBES2015

Novel targeted treatment combinations for malignant neuroendocrine tumour olfactory neuroblastoma

Young Karen , Alusi Ghassan , Korbonits Marta

Background: Olfactory neuroblastoma (ONB), a neuroendocrine nasal tumour, exhibits a range of phenotypes from indolent to very aggressive. Even early disease is associated with high (60%) recurrence rates, while advanced disease has 1.5y disease-free and 2.5y overall mean survival. Medical treatments against primary and recurrent disease as well as prognostic biomarkers are urgently required. The few studies available suggest that mTOR/MAPK and Sonic Hedgehog signalling has a ...

ea0037ep603 | Obesity and cardiovascular endocrinology | ECE2015

Adiponectin deletion impairs insulin signalling in insulin-sensitive but not insulin-resistant 3T3-L1 adipocytes

Park Cheol-Young , Chang Eugene , Kim Sungrae

Aims: Previous reports have demonstrated that the adipocyte-derived peptide adiponectin is closely associated with insulin resistance due to its insulin-sensitizing and anti-inflammatory properties in peripheral tissues; however the autocrine effects of adiponectin remain elusive. This study investigated regulatory effects of adiponectin on glucose transport and insulin signalling in insulin-sensitive or insulin-resistant 3T3-L1 adipocytes.Methods: 3T3-L...